Ibrahim Almeky, MD
Internal Medicine · Kingston, PANPI 1750477139
Payments from drug & device makers
Across 170 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$773
- AstraZeneca$449
- GSK$278
- Pfizer$232
- Biofire Diagnostics, LLC$172
- Actelion Pharmaceuticals US, Inc.$123
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,384100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $773 |
| AstraZeneca(2 entities) | 18 | $449 |
| GSK | 16 | $278 |
| Pfizer | 12 | $232 |
| Biofire Diagnostics, LLC | 3 | $172 |
| Actelion Pharmaceuticals US, Inc. | 1 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $120 |
| Astellas Pharma US Inc | 5 | $110 |
| Philips North America LLC | 4 | $104 |
| Indivior Inc. | 4 | $95 |
| Lilly USA, LLC | 6 | $87 |
| Daiichi Sankyo Inc. | 5 | $84 |
| AbbVie(2 entities) | 5 | $82 |
| Boehringer Ingelheim | 5 | $74 |
| UCB, Inc. | 3 | $63 |
| Tactile Systems Technology Inc | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 3 | $42 |
| Amgen | 2 | $34 |
| Bayer | 2 | $34 |
| Organogenesis Inc. | 1 | $33 |
| Novartis | 1 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Abbott | 1 | $23 |
| Linus Health, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,399 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,264 | $271,305 |
| RinvoqUpadacitinib | 19 | $127,184 |
| SantylCollagenase Clostridium Hist. | 28 | $106,878 |
| XifaxanRifaximin | 65 | $62,782 |
| TradjentaLinagliptin | 334 | $57,017 |
| JardianceEmpagliflozin | 173 | $52,194 |
| OzempicSemaglutide | 44 | $45,460 |
| Invega SustennaPaliperidone Palmitate | 14 | $38,015 |
| TrulicityDulaglutide | 74 | $37,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $36,071 |
| XareltoRivaroxaban | 187 | $35,324 |
| FarxigaDapagliflozin Propanediol | 106 | $32,764 |
| Potassium Chloride | 1,346 | $25,075 |
| JanuviaSitagliptin Phosphate | 94 | $24,873 |
| Atorvastatin Calcium | 2,336 | $22,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $232 | $281,8981,275 claims |
| AbbVieRinvoq, Linzess | $82 | $134,60432 claims |
| Boehringer IngelheimTradjenta, Jardiance | $74 | $109,211507 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $24 | $73,339201 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $449 | $69,055234 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $278 | $65,848152 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $120 | $62,78265 claims |
| Novo NordiskOzempic, Rybelsus | $773 | $57,67694 claims |
| Lilly USA, LLCTrulicity | $87 | $37,14574 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $19,992117 claims |
| NovartisEntresto | $30 | $10,05443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Kingston
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.